IgA Nephropathy clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
open to eligible people ages 18 years and up
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is: Is there a treatment benefit of TARPEYO® 16 mg QD extended use? Participants will - take part in this study for about 19 months - Have urine tests done - Have blood samples taken - Have physical examinations done
Orange 5379513, California 5332921 and other locations
Last updated: